INTERNATIONAL PATENT: SALUBRIS BIOTHERAPEUTICS, INC. FILES APPLICATION FOR "NEUREGULIN-1/ANTI-HER3 ANTIBODY FUSION PROTEIN FOR USE IN THE TREATMENT OF HEART FAILURE"

GENEVA, Dec. 2 -- SALUBRIS BIOTHERAPEUTICS, INC. (45 West Watkins Mill Road, Suite EGaithersburg, Maryland 20878) filed a patent application (PCT/US2025/030195) for "NEUREGULIN-1/ANTI-HER3 ANTIBODY FUSION PROTEIN FOR USE IN THE TREATMENT OF HEART FAILURE" on May 20, 2025. With publication no. WO/2025/245112, the details related to the patent application was published on Nov 27, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): MURPHY, Samuel L. (c/o Salubris Biotherapeutics, Inc.45 West Watkins Mill Road, Suite EGaithersburg, Maryland 20878), DONG, Jijun (c/o Salubris Biotherapeutics, Inc.45 W...